A monoclonal antibody (mAb) treatment being developed by Taiwan's National Health Research Institutes (NHRI) has been shown to significantly reduce levels of the COVID-19 coronavirus in infected animals, the body's leading infectious disease official said Wednesday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Watchdog censures Taichung for failing to protect abused migrant caregivers
04/18/2025 09:32 PM - Politics
Lai calls for more trade, tech collaborations with U.S.
04/18/2025 08:54 PM - Business
Taiwan passes amendment to include tax credits for AI investments
04/18/2025 08:34 PM - Society
Survey reveals lack of gender equity support at Taiwan universities
04/18/2025 08:04 PM - Culture
Taiwanese youth wins 2025 Sony Photography Award
04/18/2025 07:53 PM